Critical Analysis: Intrexon (NYSE:XON) vs. Its Peers

Intrexon (NYSE: XON) is one of 186 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it compare to its competitors? We will compare Intrexon to related companies based on the strength of its risk, dividends, analyst recommendations, earnings, institutional ownership, profitability and valuation.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Intrexon and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Intrexon 0 1 5 0 2.83
Intrexon Competitors 560 2432 6662 133 2.65

Intrexon presently has a consensus price target of $38.50, suggesting a potential upside of 191.23%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 11.77%. Given Intrexon’s stronger consensus rating and higher possible upside, analysts clearly believe Intrexon is more favorable than its competitors.

Institutional and Insider Ownership

77.5% of Intrexon shares are held by institutional investors. Comparatively, 49.5% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 56.3% of Intrexon shares are held by insiders. Comparatively, 14.8% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Intrexon and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Intrexon $190.93 million -$186.61 million -11.80
Intrexon Competitors $207.03 million -$40.51 million -63.99

Intrexon’s competitors have higher revenue and earnings than Intrexon. Intrexon is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

Intrexon has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. Comparatively, Intrexon’s competitors have a beta of 1.48, meaning that their average stock price is 48% more volatile than the S&P 500.


This table compares Intrexon and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Intrexon -66.88% -18.68% -11.34%
Intrexon Competitors -4,634.67% -42.24% -44.40%


Intrexon beats its competitors on 9 of the 13 factors compared.

About Intrexon

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. The Company’s technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing (LEAP), and ActoBiotics platform.

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply